Research and Clinical Trials

COG AALL0932 Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia
Brief Description  
AALL0932 will explore the delivery of Maintenance therapy for children with AR B-precursor ALL. This study will compare 2 different doses of methotrexate during Maintenance administered with and without a reduced frequency of vincristine/dexamethasone (VCR/DEX) pulses, every 12 weeks compared to every 4 weeks, respectively, in a 2 x 2 design.
Who may be Eligible  
Patients must have newly diagnosed NCI Standard Risk B-precursor ALL. Patients with Down syndrome are also eligible.
Patients must be > 365 days and < 10 years of age.
Patients must have an initial white blood cell count < 50 000/•L


IRB Number  
Principal Investigator  
Kaplan, Joel

For More Information, Contact  Wendy  C, Bissette
Phone:  (704) 355-9081  Fax:  (704) 355-1188  
Address:1025 Morehead Medical Drive Charlotte, NC 28204